September 12, 2025
A hope and a prayer which could offer an uncertain mix of upcoming inflation pressures
Pre-Open Signals: 1 Positive, 1 Sell into Strength and 4 Negative indications
Also, my hang-up or same-old mantra, “every time I see a new high, I am of the opinion to say BYE. And it is Friday, the escape door. Also, if the market falls back into its sideways, choppy range, sector “positions” could be back struggling and suffer.”
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
September 2, 2025
A net loss of -$18.23 M or -$0.11 per share, revenue of $317 K <cost of sales = $302 K>, a cash position of $786 K <liabilities -$1.376 M>, with a runway until Q3/25.
What happened and where is the $2 M "Exempt Offering of Securities" Trouble in offering land?
Accumulated deficit to date= $103.2 M
U.S. investors BEWARE, forewarned is forearmed?
September 12, 2025
A week of alternating negative/positive sector closes
Reiterating, “The sector is what it is, until it isn’t, even if it doesn’t seem to be, it yet will be.”
News: Merck (MRK) is moving all R&D operations out of UK, Eli Lilly (LLY) is reconsidering UK biotech incubator, pausing buildout and to top it off a report that HHC/CDC advisor/health officials plan to link Covid shots to the deaths of around 2 dozen children <see below>
Never leave an investor uninformed!
TGIF
September 2, 2025
A net loss of -$18.23 M or -$0.11 per share, revenue of $317 K <cost of sales = $302 K>, a cash position of $786 K <liabilities -$1.376 M>, with a runway until Q3/25. What happened and where is the $2 M "Exempt Offering of Securities" Trouble in offering land? Accumulated deficit to date= $103.2 M U.S. investors BEWARE, forewarned is forearmed?
August 28, 2025
Stay with me … Who is speaking-up for investors? I write this blog/newsletter about – facts in evidence! I will still answer or qualify the sector’s equity’s share pricing mobility; with an emphasis on which company is gaining or losing stride in your portfolio in the short and near-term I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
August 13, 2025
Of 32.29 M shares priced at $2.99 per share With the usual pre-funded warrants <6 M> CMPX traded down -$0.015 or -0.4732% to $3.16 mid-day Expecting gross proceeds from the offering to CMPX to be approximately $120 M
September 12, 2025
RegMed Investors (RMi) Closing Bell: Trading places
September 12, 2025
RegMed Investors’ (RMi) pre-open: Waiting for Jerome and consumer confidence
September 11, 2025
RegMed Investors (RMi) Closing Bell: The merry-go-round
September 11, 2025
RegMed Investors’ (RMi) pre-open: CPI headwinds and jobless headlights
September 10, 2025
RegMed Investors (RMi) Closing Bell: Always waiting for an all-clear signal
September 10, 2025
RegMed Investors’ (RMi) pre-open: Waiting for PPI, it's here
September 9, 2025
RegMed Investors (RMi) Closing Bell: A tug-of-war
September 9, 2025
RegMed Investors’ (RMi) pre-open: Waiting the wait
September 8, 2025
RegMed Investors (RMi) Closing Bell: Answer, RED is the color of the day
September 8, 2025
RegMed Investors’ (RMi) pre-open: On deck
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
